Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Artivion, Inc. is a U.S.-based medical device company focused on the development, manufacturing, and commercialization of products used in cardiac and vascular surgery. The company operates within the cardiovascular medical technology industry, serving hospitals and surgeons who treat complex aortic, arterial, and structural heart conditions. Artivion’s portfolio is centered on devices and biologic solutions designed for open surgical and hybrid procedures, particularly in aortic disease management.
The company’s primary revenue drivers include aortic stent grafts, surgical sealants, and cryopreserved human tissues used in cardiac and vascular reconstruction. Artivion is recognized for its specialization in complex aortic repair and for offering a differentiated portfolio that combines implantable devices, biologics, and surgical adjuncts. Formerly known as CryoLife, Inc., the company rebranded to Artivion, Inc. in 2022 to reflect its expanded focus beyond tissue preservation into advanced aortic and endovascular technologies following several strategic acquisitions.
Business Operations
Artivion operates through integrated business lines that encompass Aortic Stent Grafts, Surgical Sealants, and BioImplants, each contributing to procedural solutions for cardiovascular surgeons. The company generates revenue primarily through direct sales of implantable devices and biologic products to hospitals, supplemented by distributor relationships in select international markets. Its operations include proprietary manufacturing processes for medical devices and controlled cryopreservation and storage of human tissue.
The company maintains domestic operations in the United States and international sales activities across Europe, Asia-Pacific, and Latin America. Key subsidiaries include JOTEC GmbH, which anchors Artivion’s endovascular stent graft platform, and Endospan Ltd., which supports its aortic arch and ascending aorta technologies. Artivion also controls intellectual property related to tissue processing, polymer-based sealants, and hybrid aortic repair systems.
Strategic Position & Investments
Artivion’s strategic direction emphasizes growth in complex aortic disease treatment through innovation in hybrid and endovascular solutions that complement traditional open surgery. The company has pursued targeted acquisitions to expand its technology base, most notably JOTEC GmbH and Endospan Ltd., strengthening its position in thoracic and aortic arch stent grafts. These investments support Artivion’s long-term strategy of offering comprehensive procedural solutions rather than single-product offerings.
The company continues to invest in clinical trials, regulatory approvals, and next-generation device development, particularly in branched and frozen elephant trunk technologies for complex aortic repair. Artivion’s strategy also includes expanding indications for existing products and increasing adoption in international markets where complex aortic disease is underserved.
Geographic Footprint
Artivion is headquartered in North America, with its principal executive offices located in the United States. The company maintains a significant presence in Europe, driven largely by its German-based operations and manufacturing associated with JOTEC, as well as regulatory approvals across the European Union.
Beyond North America and Europe, Artivion markets products in Asia-Pacific and Latin America through a combination of direct sales teams and distribution partners. Its international footprint supports global clinical adoption of its aortic technologies and provides diversification across healthcare systems and regulatory environments.
Leadership & Governance
Artivion is led by an executive team with extensive experience in medical devices, cardiovascular surgery, and regulated healthcare markets. The leadership team emphasizes disciplined capital allocation, innovation in complex cardiovascular care, and close collaboration with clinicians to guide product development and clinical strategy.
Key executives include:
- Pat Mackin – President and Chief Executive Officer
- Brice McDaniel – Chief Financial Officer
- Robert McCormick – Chief Operating Officer
- Jeffrey L. Hall – Chief Legal Officer and Corporate Secretary
- David A. Roberts – Chief Technology Officer
The company’s governance framework aligns management incentives with long-term shareholder value and regulatory compliance, with a strategic vision centered on leadership in complex aortic and cardiovascular surgical solutions.